Stryker Co. (NYSE:SYK) Shares Sold by Pitcairn Co.

Pitcairn Co. decreased its position in Stryker Co. (NYSE:SYK) by 1.5% in the 4th quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The fund owned 10,529 shares of the medical technology company’s stock after selling 160 shares during the period. Pitcairn Co.’s holdings in Stryker were worth $3,791,000 as of its most recent SEC filing.

A number of other institutional investors also recently added to or reduced their stakes in SYK. Norges Bank bought a new position in Stryker during the fourth quarter valued at about $1,710,744,000. Raymond James Financial Inc. bought a new stake in shares of Stryker during the 4th quarter worth about $353,394,000. Proficio Capital Partners LLC increased its stake in shares of Stryker by 52,520.8% in the fourth quarter. Proficio Capital Partners LLC now owns 596,194 shares of the medical technology company’s stock worth $214,660,000 after purchasing an additional 595,061 shares during the period. RTW Investments LP acquired a new position in shares of Stryker during the third quarter valued at about $143,392,000. Finally, State Street Corp lifted its position in Stryker by 2.2% in the third quarter. State Street Corp now owns 14,582,959 shares of the medical technology company’s stock worth $5,279,788,000 after purchasing an additional 316,404 shares during the period. Institutional investors and hedge funds own 77.09% of the company’s stock.

Stryker Trading Up 1.2 %

Shares of NYSE SYK opened at $377.82 on Thursday. The firm has a 50-day moving average of $383.16 and a 200 day moving average of $374.45. The company has a debt-to-equity ratio of 0.59, a current ratio of 1.95 and a quick ratio of 1.32. The stock has a market cap of $144.21 billion, a P/E ratio of 48.69, a price-to-earnings-growth ratio of 2.93 and a beta of 0.95. Stryker Co. has a 1 year low of $314.93 and a 1 year high of $406.19.

Stryker (NYSE:SYK) last released its quarterly earnings results on Tuesday, January 28th. The medical technology company reported $4.01 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $3.87 by $0.14. Stryker had a return on equity of 23.58% and a net margin of 13.25%. During the same quarter in the prior year, the company posted $3.46 earnings per share. As a group, sell-side analysts expect that Stryker Co. will post 13.47 EPS for the current fiscal year.

Stryker Dividend Announcement

The company also recently declared a quarterly dividend, which will be paid on Wednesday, April 30th. Investors of record on Monday, March 31st will be issued a $0.84 dividend. The ex-dividend date is Monday, March 31st. This represents a $3.36 dividend on an annualized basis and a dividend yield of 0.89%. Stryker’s payout ratio is 43.30%.

Analyst Ratings Changes

SYK has been the topic of several research reports. Barclays upped their price target on shares of Stryker from $418.00 to $443.00 and gave the stock an “overweight” rating in a research report on Monday, February 10th. JMP Securities reissued a “market perform” rating on shares of Stryker in a research note on Tuesday, February 18th. The Goldman Sachs Group set a $422.00 price objective on Stryker in a report on Tuesday, March 4th. StockNews.com downgraded shares of Stryker from a “buy” rating to a “hold” rating in a research note on Thursday, March 6th. Finally, JPMorgan Chase & Co. boosted their target price on shares of Stryker from $420.00 to $445.00 and gave the stock an “overweight” rating in a report on Wednesday, January 29th. Five investment analysts have rated the stock with a hold rating and sixteen have given a buy rating to the company’s stock. According to data from MarketBeat, the stock presently has an average rating of “Moderate Buy” and an average target price of $421.90.

Insiders Place Their Bets

In other Stryker news, Director Allan C. Golston sold 2,458 shares of Stryker stock in a transaction dated Tuesday, February 18th. The stock was sold at an average price of $383.07, for a total transaction of $941,586.06. Following the completion of the sale, the director now owns 14,895 shares of the company’s stock, valued at approximately $5,705,827.65. The trade was a 14.16 % decrease in their position. The sale was disclosed in a legal filing with the SEC, which can be accessed through this link. Also, Director Ronda E. Stryker sold 201,392 shares of the firm’s stock in a transaction that occurred on Friday, January 31st. The stock was sold at an average price of $392.24, for a total transaction of $78,993,998.08. Following the transaction, the director now directly owns 3,642,075 shares of the company’s stock, valued at $1,428,567,498. This represents a 5.24 % decrease in their ownership of the stock. The disclosure for this sale can be found here. 5.50% of the stock is currently owned by corporate insiders.

Stryker Company Profile

Stryker Corporation operates as a medical technology company. The company operates through two segments, MedSurg and Neurotechnology, and Orthopaedics and Spine. The Orthopaedics and Spine segment provides implants for use in total joint replacements, such as hip, knee and shoulder, and trauma and extremities surgeries.